- Home
- SST vs RFL Comparison
SST vs RFL Comparison
Compare SST & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SST | RFL |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 61.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SST | RFL |
|---|---|---|
| Price | $3.10 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 5.9K | ★ 58.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.29 | $1.12 |
| 52 Week High | $11.30 | $3.19 |
Technical Indicators
Market Signals| Indicator | SST | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 76.62 |
| Support Level | $3.09 | $1.41 |
| Resistance Level | $3.57 | $1.60 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 38.61 | 75.61 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.